Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines

It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible preventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidi, Elham, Asgary, Amirhossein, Shafiekhani, Paria, Khajeamiri, Yasaman, Mohamed, Kawthar, Esmaily, Hadi, Jamal Rahi, Sahand, Mansouri, Nahal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronavirus – Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115789/
https://www.ncbi.nlm.nih.gov/pubmed/35417285
http://dx.doi.org/10.1080/21645515.2022.2037384
Descripción
Sumario:It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineʻs antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.

Ejemplares similares